Drug
Antidepressant Spd489
Antidepressant Spd489: highest development phase Phase 3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Antidepressant + SPD489 (Lisdexamfetamine dimesylate ) NCT01436162 | Phase 3 | Major Depressive Disorder |
Latest
No recent events.
Follow Antidepressant Spd489 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.